uniQure B.V. - 500 Beiträge pro Seite
eröffnet am 05.03.14 17:14:43 von
neuester Beitrag 22.03.16 16:59:37 von
neuester Beitrag 22.03.16 16:59:37 von
Beiträge: 12
ID: 1.192.115
ID: 1.192.115
Aufrufe heute: 0
Gesamt: 6.381
Gesamt: 6.381
Aktive User: 0
ISIN: NL0010696654 · WKN: A1XDTV · Symbol: UQ1
4,5350
EUR
+3,35 %
+0,1470 EUR
Letzter Kurs 22.04.24 Tradegate
Neuigkeiten
28.02.24 · globenewswire  |
15.01.24 · PR Newswire (dt.) |
19.12.23 · globenewswire |
29.11.23 · globenewswire |
07.11.23 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,0000 | +67,36 | |
| 9,4000 | +47,57 | |
| 1,4800 | +33,82 | |
| 0,7920 | +27,74 | |
| 5,5400 | +19,32 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7603 | -15,56 | |
| 1,0480 | -16,56 | |
| 6,5500 | -18,13 | |
| 0,6021 | -35,26 | |
| 3,6800 | -47,05 |
Feedback
uniQure plant 75 Mio. USD IPO an der Nasdaq
http://www.goingpublic.de/uniqure-plant-75-mio-usd-ipo-an-de…
http://www.goingpublic.de/uniqure-plant-75-mio-usd-ipo-an-de…
Gentherapien -
Die nächste Phase der Biotechbranche
http://www.faz.net/aktuell/wirtschaft/unternehmen/gentherapi…
Die nächste Phase der Biotechbranche
http://www.faz.net/aktuell/wirtschaft/unternehmen/gentherapi…
Hat die noch jemand im Blick. Nach der KE und der Kooperation mit BMS geht es ja nur noch bergab. 50 Tage Linie bald erreicht.
uniQure Added to NASDAQ Biotechnology Index December 14, 2015 9:34 AM
wollte den Thread mal wieder beleben….Related Quotes
QURE
17.90
+12.09%
uniQure N.V. Watchlist
17.90+1.93(12.09%)
NASDAQ3:00 PM EST
AMSTERDAM, the Netherlands, Dec. 14, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leader in human gene therapy, today announced that the Company has been added to the NASDAQ Biotechnology Index(R) (NBI) as part of NBI's annual selection of biotechnology and pharmaceutical companies listed on the NASDAQ Stock Market(R) that meet NBI's eligibility criteria. uniQure will be added to the NBI effective prior to market open on December 21, 2015.
… bin seit dieser Woche wieder dabei….
Gruss S.
Trading Spotlight
Antwort auf Beitrag Nr.: 51.312.267 von Schaeffi am 15.12.15 21:07:24
Tweet
Uniqure NV logoJ. Goldman & Company purchased a new position in Uniqure NV (NASDAQ:QURE) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The hedge fund purchased 142,900 shares of the company’s stock, valued at approximately $2,922,000.
Uniqure NV (NASDAQ:QURE) opened at 15.53 on Tuesday. The firm has a 50-day moving average price of $18.31 and a 200 day moving average price of $23.32. Uniqure NV has a 12 month low of $14.64 and a 12 month high of $36.38. The company’s market capitalization is $376.11 million.
142,900 Shares in Uniqure NV (QURE) Acquired by J. Goldman & Company
Posted on December 29, 2015 by Justin Garson in Investing, SEC Filing ArticlesTweet
Uniqure NV logoJ. Goldman & Company purchased a new position in Uniqure NV (NASDAQ:QURE) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The hedge fund purchased 142,900 shares of the company’s stock, valued at approximately $2,922,000.
Uniqure NV (NASDAQ:QURE) opened at 15.53 on Tuesday. The firm has a 50-day moving average price of $18.31 and a 200 day moving average price of $23.32. Uniqure NV has a 12 month low of $14.64 and a 12 month high of $36.38. The company’s market capitalization is $376.11 million.
Antwort auf Beitrag Nr.: 51.380.541 von Schaeffi am 29.12.15 15:38:55Top-line data zu Hemophilia B. soll ja in der 2. KW kommen.
Der Wechsel des CEOs wurde ja am Markt anscheinend als "böses Omen" gewertet.
Pro - fast 9 $ pro Aktie mit Cash unterlegt.
Der Wechsel des CEOs wurde ja am Markt anscheinend als "böses Omen" gewertet.
Pro - fast 9 $ pro Aktie mit Cash unterlegt.
Antwort auf Beitrag Nr.: 51.385.986 von McNay am 30.12.15 12:23:39ja genau, hatte auch was auf dem Schirm mit News Anfang 16
zu Balance Sheet
Total Cash (mrq): 235.18M
Total Cash Per Share (mrq): 9.71
Total Debt (mrq): 20.07M
Total Debt/Equity (mrq): 14.03
Current Ratio (mrq): 9.27
Book Value Per Share (mrq): 5.91
dahin wird's auch gehen wenn neg. News kommen.
und zu:
Hemophilia B
Hemophilia B is a serious rare inherited disease in males characterized by insufficient blood clotting. The condition can lead to repeated and sometimes life-threatening episodes of external and internal bleeding following accidental trauma or medical interventions. The episodes can cause long-term damage, for example to the joints, and can be fatal if they occur in the brain. The deficient blood clotting results from the lack of functional human Factor IX, or hFIX, a blood clotting factor, as a result of mutations in the relevant gene.
Treatment of hemophilia B today consists of prophylactic or on-demand protein replacement therapy, in which frequent intravenous administrations of plasma-derived or recombinant hFIX are required to stop or prevent bleeding. Protein replacement therapy is expensive, often costing approximately $220,000 to $340,000 per patient per year in the United States. Such therapy is also burdensome and does not completely prevent bleeding.
uniQure’s hemophilia B gene therapy program aims to restore the function of blood clotting on a long-term and potentially curative basis through the delivery of the functional gene for hFIX into the patients’ liver cells. In a Phase I/II gene therapy trial being carried out by St. Jude using the same therapeutic gene cassette we have licensed and delivered in an AAV8 vector, interim data showed that the vector consistently led to long-term expression of the hFIX transgene at therapeutic levels in patients with severe hemophilia B, without acute or long-lasting toxicity.
The company has already obtained orphan drug designation for its hemophilia B therapy in the European Union.
There is excitement in the hemophilia community, both from the side of patients and from physicians and researchers, about the potential benefits of gene therapy for the health and quality of life of hemophiliacs. The potential that a successful gene therapy would allow hemophiliacs to forego prophylactic treatment in the future would be life changing.
time will tell….
Gruss S.
zu Balance Sheet
Total Cash (mrq): 235.18M
Total Cash Per Share (mrq): 9.71
Total Debt (mrq): 20.07M
Total Debt/Equity (mrq): 14.03
Current Ratio (mrq): 9.27
Book Value Per Share (mrq): 5.91
dahin wird's auch gehen wenn neg. News kommen.
und zu:
Hemophilia B
Hemophilia B is a serious rare inherited disease in males characterized by insufficient blood clotting. The condition can lead to repeated and sometimes life-threatening episodes of external and internal bleeding following accidental trauma or medical interventions. The episodes can cause long-term damage, for example to the joints, and can be fatal if they occur in the brain. The deficient blood clotting results from the lack of functional human Factor IX, or hFIX, a blood clotting factor, as a result of mutations in the relevant gene.
Treatment of hemophilia B today consists of prophylactic or on-demand protein replacement therapy, in which frequent intravenous administrations of plasma-derived or recombinant hFIX are required to stop or prevent bleeding. Protein replacement therapy is expensive, often costing approximately $220,000 to $340,000 per patient per year in the United States. Such therapy is also burdensome and does not completely prevent bleeding.
uniQure’s hemophilia B gene therapy program aims to restore the function of blood clotting on a long-term and potentially curative basis through the delivery of the functional gene for hFIX into the patients’ liver cells. In a Phase I/II gene therapy trial being carried out by St. Jude using the same therapeutic gene cassette we have licensed and delivered in an AAV8 vector, interim data showed that the vector consistently led to long-term expression of the hFIX transgene at therapeutic levels in patients with severe hemophilia B, without acute or long-lasting toxicity.
The company has already obtained orphan drug designation for its hemophilia B therapy in the European Union.
There is excitement in the hemophilia community, both from the side of patients and from physicians and researchers, about the potential benefits of gene therapy for the health and quality of life of hemophiliacs. The potential that a successful gene therapy would allow hemophiliacs to forego prophylactic treatment in the future would be life changing.
time will tell….
Gruss S.
Antwort auf Beitrag Nr.: 46.569.899 von pickuru am 05.03.14 17:17:49
Jan 6, 2016
uniQure Announces Conference Call and Webcast to Discuss Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial
Amsterdam, the Netherlands, January 6, 2016 — uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that the Company will release topline results from its Hemophilia B Phase I/II gene therapy low-dose cohort clinical trial through a press release at 06:00 EST/12:00 CET on January 7, 2016. The Company’s management team will hold a conference call and webcast at 08:30 EST/14:30 CET after the press release has been issued to discuss the update.
The conference call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code: 1640435. The webcast, including accompanying slides also available as a PDF file, can be accessed through the link displayed in the “Events” section on the “Media” page of the uniQure website at http://www.uniqure.com/news/calendar-of-events/. The webcast replay will be available for at least 72 hours following the call.
Conference Call Numbers
London, United Kingdom: +44 (0) 20 3427 1906
New York, United States of America: +1 212 444 0412
Berlin, Germany: +49 (0) 30 3001 90534
Amsterdam, Netherlands: +31 (0) 20 716 8296
Paris, France: +33 (0) 1 76 77 22 31
Milan, Italy: +39 02 3859 1420
Brussels, Belgium: +32 (0) 2 402 3092
Montreal, Canada: +1 514 841 2154
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
CONTACT
uniQure:
Direct: +31 20 240 6110
Main: +31 20 240 6000
e.mulder@uniQure.com
Heute Veröffentlichung Studeinergebnisse
uniQure Announces Conference Call and Webcast to Discuss Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial Jan 6, 2016
uniQure Announces Conference Call and Webcast to Discuss Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial
Amsterdam, the Netherlands, January 6, 2016 — uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that the Company will release topline results from its Hemophilia B Phase I/II gene therapy low-dose cohort clinical trial through a press release at 06:00 EST/12:00 CET on January 7, 2016. The Company’s management team will hold a conference call and webcast at 08:30 EST/14:30 CET after the press release has been issued to discuss the update.
The conference call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code: 1640435. The webcast, including accompanying slides also available as a PDF file, can be accessed through the link displayed in the “Events” section on the “Media” page of the uniQure website at http://www.uniqure.com/news/calendar-of-events/. The webcast replay will be available for at least 72 hours following the call.
Conference Call Numbers
London, United Kingdom: +44 (0) 20 3427 1906
New York, United States of America: +1 212 444 0412
Berlin, Germany: +49 (0) 30 3001 90534
Amsterdam, Netherlands: +31 (0) 20 716 8296
Paris, France: +33 (0) 1 76 77 22 31
Milan, Italy: +39 02 3859 1420
Brussels, Belgium: +32 (0) 2 402 3092
Montreal, Canada: +1 514 841 2154
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
CONTACT
uniQure:
Direct: +31 20 240 6110
Main: +31 20 240 6000
e.mulder@uniQure.com
nach guten Ergebnissen wieder abverkauft
der Markt und Biotech/Gentech im speziellen haben grad keinen guten Stand
keine Ahnung wann das wieder dreht
kann nächste Woche seine oder erst nächstes Jahr
wieder an der Seitenlinie.
cash is king erst mal
der Markt und Biotech/Gentech im speziellen haben grad keinen guten Stand
keine Ahnung wann das wieder dreht
kann nächste Woche seine oder erst nächstes Jahr
wieder an der Seitenlinie.
cash is king erst mal
wenn ich mit die Keys so anschaue sind das für mich jetzt Kaufkurse
++++++++++++++++++++++
uniQure N.V. (QURE) -NasdaqGS
11.60 Up 0.46(4.13%) 1:42PM EDT - Nasdaq Real Time Price
Key Statistics Get Key Statistics for:
Data provided by Capital IQ, except where noted.
Valuation Measures
Market Cap (intraday)5: 280.94M
Balance Sheet
Total Cash (mrq): 238.27M
Total Cash Per Share (mrq): 9.84
Total Debt (mrq): 20.34M
Total Debt/Equity (mrq): 14.03
Current Ratio (mrq): 9.27
Book Value Per Share (mrq): 5.98
++++++++++++++++++++++++++
fast auf Cash - Pipeline und das erste zugelassene Medi fast umsonst...
++++++++++++++++++++++
uniQure N.V. (QURE) -NasdaqGS
11.60 Up 0.46(4.13%) 1:42PM EDT - Nasdaq Real Time Price
Key Statistics Get Key Statistics for:
Data provided by Capital IQ, except where noted.
Valuation Measures
Market Cap (intraday)5: 280.94M
Balance Sheet
Total Cash (mrq): 238.27M
Total Cash Per Share (mrq): 9.84
Total Debt (mrq): 20.34M
Total Debt/Equity (mrq): 14.03
Current Ratio (mrq): 9.27
Book Value Per Share (mrq): 5.98
++++++++++++++++++++++++++
fast auf Cash - Pipeline und das erste zugelassene Medi fast umsonst...
BRIEF-Uniqure announces preclinical data supporting gene therapy program, AMT-130
March 22 (Reuters) - Uniqure Nv QURE.O :
* Says publication of preclinical data supporting its
proprietary Huntington's disease gene therapy program, AMT-130
* Based on the results, Uniqure has initiated further
studies of AMT-130 to support filing of an investigative new
drug application with FDA
Source text for Eikon: [ID:nGNXVFCJVa]
Further company coverage:
*******
das war der Boden
March 22 (Reuters) - Uniqure Nv QURE.O :
* Says publication of preclinical data supporting its
proprietary Huntington's disease gene therapy program, AMT-130
* Based on the results, Uniqure has initiated further
studies of AMT-130 to support filing of an investigative new
drug application with FDA
Source text for Eikon: [ID:nGNXVFCJVa]
Further company coverage:
*******
das war der Boden
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +1,91 | |
| +0,61 | |
| -0,91 | |
| +0,19 | |
| -0,57 | |
| +1,72 | |
| +0,47 | |
| +1,15 | |
| +0,98 | |
| -1,02 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 189 | ||
| 129 | ||
| 80 | ||
| 78 | ||
| 50 | ||
| 44 | ||
| 41 | ||
| 32 | ||
| 30 | ||
| 26 |
uniQure B.V.
